Medication info
TVF Tablet 125 mg (Terbinafine Hydrochloride)

TVF Tablet 125 mg (Terbinafine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Terbinafine Hydrochloride›140.625mg / 1 tablet
Manufacturer / importer
Donghwa Pharmaceutical Co., Ltd.
Appearance
White to whitish round tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200100779 · Notified 2001.05.15 · Insurance code 642703200

Summary

Main use
Treatment of cutaneous fungal infections (e.g., tinea pedis and tinea corporis), onychomycosis, and tinea capitis
Who takes it
Adults · Children
Adult dose
1. Adults Administer 125 mg of terbinafine per dose twice daily or 250 mg per dose once daily. The treatment duration according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is usually administered for 6 weeks~3 months. The treatment period may be shortened to 3 months or less if the infection involves a fingernail or a relatively small toenail, or if the patient is young. A treatment period of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. The treatment period may be longer in patients with slow nail growth. 3. Patients with renal impairment Reduce the daily dose by 1/2 in patients with a creatinine clearance of less than 50 mL per minute.
Child dose
2. Children: Administer to children aged 2 years and older. Administration is not recommended for children under 2 years of age because there is no experience with its use in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of the infection, treatment must be given regularly for an adequate, specified period. 1) Body weight less than 20 kg (under 5 years): Administer 62.5 mg per dose once daily. Because experience with treatment is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. 2) Body weight 20~40 kg (5~12 years): Administer 125 mg per dose once daily. 3) Body weight over 40 kg (over 12 years): Administer 250 mg per dose once daily.

Ingredients

Manufacturer
Donghwa Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of cutaneous fungal infections (e.g., tinea pedis and tinea corporis), onychomycosis, and tinea capitis

  • Skin fungal infections
  • tinea pedis
  • tinea corporis
  • tinea cruris
  • onychomycosis
  • tinea capitis
View approved original text

This medication is used to treat various skin fungal infections caused by dermatophytes, including tinea pedis, tinea corporis, and tinea capitis in adults. It is also effective for treating tinea capitis in children. It helps improve fungal infections primarily occurring in the skin and nails.

How to take

Adult dose

1. Adults Administer 125 mg of terbinafine per dose twice daily or 250 mg per dose once daily. The treatment duration according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is usually administered for 6 weeks~3 months. The treatment period may be shortened to 3 months or less if the infection involves a fingernail or a relatively small toenail, or if the patient is young. A treatment period of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. The treatment period may be longer in patients with slow nail growth. 3. Patients with renal impairment Reduce the daily dose by 1/2 in patients with a creatinine clearance of less than 50 mL per minute.

Child dose

2. Children: Administer to children aged 2 years and older. Administration is not recommended for children under 2 years of age because there is no experience with its use in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of the infection, treatment must be given regularly for an adequate, specified period. 1) Body weight less than 20 kg (under 5 years): Administer 62.5 mg per dose once daily. Because experience with treatment is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. 2) Body weight 20~40 kg (5~12 years): Administer 125 mg per dose once daily. 3) Body weight over 40 kg (over 12 years): Administer 250 mg per dose once daily.

Precautions

This medication should generally not be used in patients with chronic liver disease or active liver disease. It is essential to check for a history of liver disease before administration, and regular liver function tests should be conducted before and during treatment. If liver function test results increase, administration should be stopped immediately, and if symptoms such as nausea, fatigue, or jaundice appear, the doctor should be notified immediately. This medication can rarely cause severe liver damage, so if liver function abnormalities are suspected, prompt evaluation and discontinuation of the treatment are necessary. Patients with allergies to this medication or its components, blood disorders, severe renal failure, infants under 2 years of age, and breastfeeding mothers should not use it. It is also safe for patients with lactose intolerance to avoid this medication. Patients with impaired kidney function, elderly individuals, and underweight children should use it with caution, and if severe rashes or allergic reactions occur, administration should be discontinued immediately. This medication should only be used for difficult-to-treat fungal infections, and if side effects such as dizziness occur, driving or operating machinery should be avoided. There may be interactions with other medications when taken together, so it is essential to consult with a doctor or pharmacist before taking it, especially with drugs that are metabolized in the liver. Women who are pregnant or who may become pregnant should use this medication only after thoroughly considering its benefits and risks, and breastfeeding women should discontinue nursing while taking it. Children and elderly individuals may experience increased drug concentration due to reduced liver and kidney function, so they should be closely monitored during treatment. Overdosage may result in headache, nausea, abdominal pain, dizziness, etc., and medical assistance should be sought immediately for proper treatment. This medication should be kept out of reach of children and stored in a tightly closed container, protected from direct sunlight and at room temperature.

Side effects

Liver failure, hepatitis, cholestasis, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, fatigue, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, petechiae, leukopenia, anemia, rash, itching, photosensitivity reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin eruptions, exfoliative dermatitis, blistering dermatitis, psoriasis-like rash, worsening of psoriasis, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, elevated myoglobin, hypotension, dyspnea, chest tightness, urticaria, erythema, facial edema, lymphangiectasia, abdominal distension, decreased appetite, dyspepsia, nausea, mild abdominal pain, diarrhea, discomfort in the stomach, thirst, vomiting, glossitis, depression, anxiety, headache, taste disturbances, dizziness, drowsiness, sensory disturbances, sensory loss, decreased attention, insomnia, elevated BUN, polyuria, visual disturbances, tinnitus, anaphylactic-like reactions, angioedema, systemic lupus erythematosus, elevated total cholesterol in the blood, elevated triglyceride levels, fatigue, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reactions, serum sickness-like reactions, blurred vision, decreased vision, hearing loss, auditory dysfunction, vasculitis, permanent loss of smell, hyposmia, drug rash, pancreatitis, rhabdomyolysis, influenza-like illness, increased serum creatine phosphokinase

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air and moisture, preferably at a temperature between 1 to 30 degrees Celsius. This storage method helps maintain the drug's efficacy and prevents deterioration.

Appearance and packaging

Appearance

White to whitish round tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.